convent
wholestool
fmt
introduc
sourc
heterogen
therefor
perform
anoth
sensit
analysi
exclud
phase
studi
result
similar
overal
cure
rate
ci
figur
comment
engraft
offer
potenti
explan
lower
rate
success
report
control
trial
howev
awar
publish
data
studi
directli
compar
microbi
engraft
convent
fmt
given
concern
rais
also
perform
analysi
exclud
studi
overal
cure
rate
still
remain
lower
report
observ
studi
ci
figur
therefor
result
sensit
analys
remov
either
studi
question
significantli
impact
point
estim
cure
clinic
trial
lower
report
observ
studi
howev
acknowledg
upper
bound
ci
approach
result
seen
observ
studi
addit
complet
agre
acknowledg
need
optim
standard
microbi
replac
product
term
formul
dose
deliveri
time
among
paramet
sever
product
develop
address
issu
hope
advanc
scienc
comment
govern
fund
agenc
commerci
develop
us
food
drug
administr
approv
process
relat
scope
current
publish
studi
potenti
conflict
interest
k
serv
consult
shire
plc
probiotech
llc
facil
therapeut
premier
inc
receiv
research
support
rebiotix
inc
outsid
submit
work
p
serv
consult
merck
therapeut
salix
pharmaceut
receiv
research
support
sere
therapeut
outsid
submit
work
author
submit
icmj
form
disclosur
potenti
conflict
interest
conflict
editor
consid
relev
content
manuscript
disclos
editorw
read
great
interest
articl
publish
foolad
et
al
compar
oral
aerosol
inhal
ribavirin
treatment
respiratori
syncyti
viru
rsv
infect
hematopoiet
stem
cell
transplant
hsct
recipi
popul
current
guidelin
recommend
treatment
rsv
infect
high
risk
diseas
progress
death
either
aerosol
system
ribavirin
howev
support
evid
use
ribavirin
context
larg
retrospect
limit
inhal
formul
use
oral
ribavirin
highrisk
hsct
patient
well
studi
foolad
et
al
sought
compar
rate
diseas
progress
mortal
rsvposit
hsct
recipi
treat
oral
versu
inhal
ribavirin
feel
area
signific
clinic
interest
use
inhal
ribavirin
come
consider
challeng
author
conclud
outcom
similar
treat
aerosol
oral
ribavirin
suggest
oral
ribavirin
may
suitabl
treatment
altern
patient
believ
conclus
present
studi
taken
follow
context
previou
data
recommend
use
ribavirin
hsct
patient
rsv
infect
show
signific
benefit
use
specif
highrisk
patient
unclear
whether
benefit
exist
use
lowto
moderaterisk
patient
studi
popul
studi
classifi
high
risk
wherea
major
patient
classifi
low
moder
risk
thu
conclus
reveal
differ
overal
mortal
rate
use
oral
inhal
ribavirin
may
primarili
due
inclus
lowto
moderaterisk
patient
may
benefit
ribavirin
treatment
moreov
outcom
stratifi
immunodefici
score
index
isi
found
small
proport
highrisk
patient
includ
studi
similar
mortal
rate
whether
receiv
oral
aerosol
ribavirin
note
total
number
patient
studi
classifi
high
risk
receiv
aerosol
ribavirin
receiv
oral
ribavirin
total
highrisk
patient
studi
may
underpow
detect
meaning
differ
treatment
group
subset
patient
addit
applic
isi
develop
origin
allogen
hsct
recipi
studi
popul
made
larg
proport
autolog
hsct
recipi
may
introduc
error
accuraci
risk
stratif
patient
awar
valid
isi
autolog
hsct
recipi
compliment
author
undertak
import
studi
believ
juri
still
regard
use
oral
ribavirin
clinic
practic
especi
rsvposit
hsct
recipi
high
risk
diseas
progress
andor
mortal
perhap
newer
strategi
hold
key
success
manag
diseas
editorw
thank
jain
et
al
thought
comment
studi
compar
outcom
treatment
oral
vs
aerosol
ribavirin
rbv
hematopoiet
cell
transplant
hct
recipi
respiratori
syncyti
viru
rsv
infect
signific
increas
cost
aerosol
rbv
per
day
random
control
trial
oral
vs
aerosol
rbv
treatment
rsv
hct
recipi
unlik
undertaken
owe
financi
restrict
mani
institut
includ
adopt
oral
rbv
altern
therapi
rsv
infect
hct
recipi
limit
retrospect
studi
mind
aim
identifi
signal
wors
outcom
switch
formul
occur
center
agre
jain
et
al
highrisk
allogen
hct
patient
defin
shah
et
al
rsv
infect
like
benefit
treatment
aerosol
rbv
reduct
rate
progress
lower
respiratori
tract
infect
lrti
mortal
howev
acknowledg
number
highrisk
patient
limit
studi
previou
studi
thu
analysi
may
underpow
detect
differ
outcom
aerosol
oral
rbv
subset
patient
hand
shah
et
al
demonstr
notabl
benefit
moderaterisk
group
well
treatment
rbv
reduc
lrti
rate
risk
ratio
confid
interv
thu
believ
role
antivir
therapi
moderaterisk
patient
typic
practic
oral
aerosol
formul
rbv
regardless
data
detect
signal
wors
outcom
oral
therapi
fact
mortal
rate
numer
higher
aerosol
group
oral
group
studi
includ
autolog
allogen
transplant
recipi
chose
includ
autolog
transplant
recipi
patient
risk
rsvassoci
morbid
mortal
may
benefit
treatment
rbv
although
immunodefici
score
index
develop
basi
cohort
allogen
hct
recipi
may
use
identifi
autolog
hct
patient
higher
risk
poor
outcom
rsv
nonetheless
agre
valid
need
final
oral
rbv
inexpens
may
administ
outpati
therapi
limit
side
effect
use
short
durat
eagerli
await
newer
strategi
manag
rsv
infect
hct
recipi
believ
current
data
oral
rbv
rsv
somewhat
support
use
altern
aerosol
rbv
antivir
therapi
potenti
conflict
interest
r
f
c
report
grant
institut
gilead
receiv
person
fee
ablynx
jnj
adma
biolog
outsid
submit
work
f
f
potenti
conflict
author
submit
icmj
form
disclosur
potenti
conflict
interest
conflict
editor
consid
relev
content
manuscript
disclos
